Testing the right aspirin dose for COPD symptoms
Treatments studied
Part of Lungs & breathing clinical trials.
This Phase 3 trial studies which aspirin dose works best in people with COPD, with the goal of improving disease control. You may be asked to take aspirin and be monitored for safety, especially bleeding risk and heart/brain history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 40 or older
- You used to smoke, and you have at least a 10 pack-year smoking history
- Your lung test shows airflow limitation (FEV1/FVC is below 0.7 after using an inhaler)
- You do NOT have a past heart attack, stent procedure, or stroke
- You are not taking blood thinners or antiplatelet medicines (other than aspirin 81 mg)
- You can safely take aspirin (no major bleeding history or aspirin allergy, and no recent major surgery)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.
This study looks at how taking aspirin at different times of day affects your body. It aims to understand the best time to take aspirin for heart health and other benefits.
This study compares whether a lower dose of aspirin (50 mg) works as well as a standard dose (100 mg) for older adults who have had heart attacks, strokes, or other heart and blood vessel problems. The goal is to find the safest effective dose to prevent future events.
This trial tests whether daily aspirin is safe and effective for people who have stable (chronic) coronary artery disease but cannot have procedures to open blocked arteries. It may help reduce future heart problems, while also checking for side effects and risks from aspirin.
This trial tests whether a daily low dose of aspirin can help older adults recover from pneumonia. It aims to reduce inflammation and improve outcomes for patients hospitalized with the infection.
This trial tests whether older adults with stable heart disease can safely stop taking daily aspirin after two years without increasing the risk of heart attack or stroke. It may help reduce the side effects of long-term aspirin use.
Hear when a new Pulmonary Disease, Chronic Obstructive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.